Vigil Neuroscience 将来の成長

Future 基準チェック /26

Vigil Neuroscience利益と収益がそれぞれ年間15.9%と77.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-135.5% 32.2%なると予測されています。

主要情報

15.9%

収益成長率

32.2%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	77.9%
将来の株主資本利益率	-135.5%
アナリストカバレッジ	Good
最終更新日	19 Nov 2024

今後の成長に関する最新情報

Recent updates

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

Oct 17

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

May 30

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29

業績と収益の成長予測

NasdaqGS:VIGL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	14	-108	-96	-157	5
12/31/2025	0	-97	-94	-108	7
12/31/2024	N/A	-84	-80	-71	7
9/30/2024	N/A	-83	-49	-49	N/A
6/30/2024	N/A	-84	-70	-70	N/A
3/31/2024	N/A	-83	-70	-70	N/A
12/31/2023	N/A	-83	-71	-70	N/A
9/30/2023	N/A	-79	-73	-72	N/A
6/30/2023	N/A	-76	-72	-71	N/A
3/31/2023	N/A	-73	-70	-69	N/A
12/31/2022	N/A	-68	-66	-65	N/A
9/30/2022	N/A	-63	-66	-65	N/A
6/30/2022	N/A	-56	-61	-61	N/A
3/31/2022	N/A	-50	-53	-53	N/A
12/31/2021	N/A	-43	-40	-39	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VIGL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VIGL今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VIGL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VIGLの収益 ( 77.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: VIGLの収益 ( 77.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VIGL 3 年以内に赤字になると予測されています。

Vigil Neuroscience 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 9.8% to US$17.57

Price target increased by 8.4% to US$18.57

Price target increased by 10% to US$18.86

Price target decreased by 14% to US$17.13

Recent updates

Price target increased by 9.8% to US$17.57

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

General Counsel & Corporate Secretary notifies of intention to sell stock

Vigil Neuroscience, Inc. Announces U.S. Food and Drug Administration Removal the Partial Clinical Hold on its Ongoing Phase 1 Clinical Trial of VG-3927

New major risk - Financial position

Vigil Neuroscience, Inc. Announces Interim Data from Its Ongoing Phase 1 Clinical Trial Evaluating Vv-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Vigil Neuroscience, Inc. Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell Small Cap Comp Value Index

Vigil Neuroscience, Inc. announced that it expects to receive $39.99997 million in funding from Sanofi Pasteur Biologics, LLC, Aventis Inc.

Vigil Neuroscience, Inc. announced that it has received $3.999997 million in funding from Sanofi Pasteur Biologics, LLC

New major risk - Share price stability

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

New major risk - Revenue and earnings growth

Price target increased by 8.4% to US$18.57

New minor risk - Market cap size

Vigil Neuroscience, Inc., Annual General Meeting, Jun 05, 2024

Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting

New minor risk - Shareholder dilution

Price target increased by 10% to US$18.86

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces Executive Changes

New minor risk - Market cap size

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

New minor risk - Market cap size

Price target decreased by 14% to US$17.13

Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927

Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP

Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting

New major risk - Share price stability

Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Appoints Samantha Budd Haeberlein to Its Board of Directors

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Announces Resignation of Shaan Gandhi, from Member of Board of Directors

High number of new and inexperienced directors

Vigil Neuroscience, Inc. Announces Executive Changes

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Vigil Neuroscience, Inc. announced that it has received $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience, Inc. announced that it expects to receive $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience announces $75M PIPE financing

Vigil Neuroscience Appoints Suzanne Bruhn to Its Board of Directors

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Growth Index

Vigil Neuroscience, Inc. Expands VGL101 Phase 1 Trial to Australia

Vigil Neuroscience, Inc. Appoints Christopher Verni as General Counsel and Mary Thistle to Its Board of Directors

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Vigil Neuroscience, Inc. has completed an IPO in the amount of $98 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘